Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Total Liabilities (2016 - 2025)

vTv Therapeutics' Total Liabilities history spans 12 years, with the latest figure at -$64.4 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 368.88% year-over-year to -$64.4 million; the TTM value through Dec 2025 reached -$64.4 million, down 368.88%, while the annual FY2025 figure was -$64.4 million, 368.88% down from the prior year.
  • Total Liabilities for Q4 2025 was -$64.4 million at vTv Therapeutics, down from $29.0 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $29.6 million in Q2 2022 and bottomed at -$64.4 million in Q4 2025.
  • The 5-year median for Total Liabilities is $25.6 million (2024), against an average of $18.4 million.
  • The largest annual shift saw Total Liabilities surged 233.11% in 2022 before it crashed 368.88% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $10.3 million in 2021, then soared by 167.26% to $27.4 million in 2022, then increased by 7.91% to $29.6 million in 2023, then dropped by 18.95% to $24.0 million in 2024, then plummeted by 368.88% to -$64.4 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Total Liabilities are -$64.4 million (Q4 2025), $29.0 million (Q3 2025), and $24.0 million (Q2 2025).